Strongbridge Biopharma

About:

Strongbridge Biopharma is a clinical and financial foundation to connect patients with new treatments for rare diseases.

Website: http://www.strongbridgebio.com/

Top Investors: RA Capital Management, New Enterprise Associates, Horizon Technology Finance, HealthCap, CRG

Description:

Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.